Neurological diseases, including Parkinson’s and Alzheimer’s, continue to be a significant global health challenge. Progress has been hindered by a number of bottlenecks, despite considerable ...

If you’re working on standard-cell libraries at 28 nm or below, you already know the math isn’t in your favor. At the 130 nm ...

A new type of cell therapy shows promise as the first treatment for advanced liver disease, following results from a clinical ...

A new type of cell therapy shows promise as the first treatment for advanced liver disease, following results from a clinical trial. Patients with the condition who were treated with the cell therapy ...

We're committing to invest $19 billion in California through 2030 to connect more Californians to the best and largest network and upgrade customers to better products to meet our customers' needs for ...

New Phase’s technology destroys cancer cells with nanoparticles and electromagnetic hyperthermia in patients with late-stage cancer.

Please provide your email address to receive an email when new articles are posted on . Two studies highlight the potential of gene editing for sickle cell disease treatment. Despite increasing ...

OneCyte, which focuses on high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, which specializes in protein engineering and expression solutions, signed a ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

When you have advanced renal cell carcinoma (RCC), both the cancer and its treatments can cause symptoms such as pain, low energy, and poor sleep — all of which can take a toll on your quality of life ...

P3 Global Intel claims that it has “quickly become the new standard in tip management for Crime Stoppers programs, [Law Enforcement Agencies], and government agencies helping to solve and prevent ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...